Clincosm LogoSign in Get a demo

Radiomics in Pancreatic Cancer

Sponsor
Ruijin Hospital (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT05658679
Collaborator
(none)
2,000
Enrollment
107
Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

The images of patients with pancreatic cancer were collected and analyzed based on the methodes of radiomics

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    2000 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Retrospective
    Official Title:
    Radiomics-based Detection and Outcome Prediction for Pancreatic Cancer
    Actual Study Start Date :
    Jan 1, 2016
    Anticipated Primary Completion Date :
    Dec 1, 2023
    Anticipated Study Completion Date :
    Dec 1, 2024

    Arms and Interventions

    Arm Intervention/Treatment
    patients with pancreatic cancer

    Patients with pancreatic tumors diagnosed clinically or pathologically
    Participants without pancreatic cancer

    Participants who judged the pancreas to be completely healthy through medical examination

    Outcome Measures

    Primary Outcome Measures

    1. 5-year survival rate [1 week]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    • Gender unlimited, 18-80 years old;

    • Received abdominal imaging;

    • informed consent signed.

    Exclusion Criteria:

    • Pregnant / lactating womenï¼›

    • Contraindications of imaging examination。

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Ruijin Hospital

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Weishen WANG, Principal Investigator, Ruijin Hospital
    ClinicalTrials.gov Identifier:
    NCT05658679
    Other Study ID Numbers:
    • Retro-001
    First Posted:
    Dec 21, 2022
    Last Update Posted:
    Dec 21, 2022
    Last Verified:
    Dec 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Pancreatic Neoplasms

    Study Results

    No Results Posted as of Dec 21, 2022